e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report: March 7, 2006
(Date of earliest event reported)
ORTHOLOGIC CORP.
 
(Exact name of registrant as specified in its charter)
         
Delaware   000-21214   86-0585310
         
(State or other jurisdiction of
incorporation)
  (Commission File Number)   (I.R.S. Employer
Identification No.)
     
1275 West Washington Street, Tempe, Arizona
  85281
 
   
(Address of principal executive offices)
  (Zip Code)
Registrant’s telephone number, including area code:
(602) 286-5520
     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
  o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
  o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
  o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
  o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 


 

Section 8 — Other Events
Item 8.01 Other Events.
     On March 7, 2006, OrthoLogic Corp. issued a press release announcing revised guidance for the expected release of topline results from its Phase 3 clinical trial of Chrysalin® (TP508) in fracture repair. Management now expects to communicate topline results by March 31, 2006, which is revised from previously provided guidance of April 30, 2006. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

 


 

Section 9 — Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
     
Exhibit No.   Description
 
   
99.1
  Press release dated March 7, 2006

 


 

SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
     Dated: March 7, 2006
  ORTHOLOGIC CORP.    
 
       
 
       
 
  /s/ Dr. James M. Pusey
 
   
 
  James M. Pusey    
 
  Chief Executive Officer